莫西沙星联合抗结核药治疗耐药性结核临床疗效观察

Effects of moxifloxacin combined with regimen in the treatment of patients with drug-resistant pulmonary tuberculosis

目的观察莫西沙星联合常规结核化疗方案治疗耐药性肺结核的临床疗效和安全性。方法收集我院结核科诊治的耐药性肺结核患者74例,将患者随机分为常规化疗对照组(n=37)和莫西沙星联合治疗组(n=37)。分析两组患者的痰菌阴转率、临床治疗效果和不良反应发生率。结果疗程结束后治疗组的痰菌阴转率为93.3%,显著高于对照组的62.5%(P<0.05)。疗程结束后治疗组总有效率为83.3%,对照组为56.2%,两组之间有显著性差异(P<0.05)。对照组和治疗组临床不良反应的发生率分别为31.2%和33.4%,两组之间无统计学差异(P>0.05)。结论莫西沙星联合常规结核化疗方案治疗耐药性肺结核临床疗效显著。

Objective To investigate the clinic effect and safety of moxifloxacin combined with regimen in the treatment of patients with drug - resistant pulmonary tuberculosis. Methods A total of 74 drug-resistant pulmonary tuberculosis patients were collected in this study. The 74 cases were randomly and evenly divided into two groups. The sputum negative conversion rates, clinic and side effects of drugs were compared between the two groups. Results 12 months after the treatment, the sputum negative conversion rates in the treatment group was higher than that in the control group （ P 〈 0.05 ）. At the end of treatment the sputum negative conversion rates in the treatment group was 93.3 % and 62.5% in the controls （P 〈 0. 05 ）. The effective rate in the treatment group was 83.3 %, and in the control group it was 56. 2%. There was significant different between the two groups （P 〈 0, 05 ）. The rates of side effects were 31.2% and 33.4% in the control group and the treatment group respectively with no significant different （ P 〉 0. 05）. Conclusion Moxifloxacin combined with regimen can effectively treat patients with drug - resistant pulmonary tuberculosis, which is worth to be promoted in clinical application.